PubMed Health⌕ Search

Biomedical subjects

G Cartei

Publications and source records attributed to G Cartei.

100 records · Page 6Linked to original sources
PubMedDate not supplied

Occult small cell lung cancer associated with paraneoplastic neurologic syndrome: case report.

Cancer is often associated with paraneoplastic syndromes, which may be misinterpreted. We report a case of a patient with occult small cell lung cancer that was initially compounded by clinical features of a paraneoplastic neurologic syndrome. The presence of antineuronal antibodies and positron emission tomography scan guided the search for the underlying tumor. Following chemo-radiotherapy the patient showed no evidence of disease for the next 18 months, whereas only a slight improvement in the neurologic disorders was observed. The course of the small cell lung cancer was very indolent and the paraneoplastic neurologic syndrome did not worsen with the use of cisplatin.

Ataxia↗
PubMedDate not supplied

Tamoxifen in disseminated breast cancer.

86 postmenopausal women with disseminated breast cancer have been treated orally with 30 mg of Tamoxifen per day (ICI 46474, Nolvadex) for periods of 2 months or more. The overall responders were 28/86 (32.5%) with a median remission duration of 9 months. In 30 patients already shown to be resistant to cytotoxic chemotherapy. Tamoxifen was used as first hormonal agent; the remission rate in this group was 12/30 (40%), while it was 28.5% (16/56) in the others who had already received different hormonal treatments. In 6 early menopausal cases, the treatment had to be stopped for a dangerous "worsening syndrome". Other side effects were trivial. In 28/35 cases (80%), we have found the reappearance of a pattern of estrogenic activity in vaginal smears during treatment. Hence a "simil-estrogen", more than an "anti-estrogen" mechanism of action is postulated and a selection of patients for treatment in the "mid postmenopausal age" is recommended.

Breast Neoplasms↗
PubMedDate not supplied

Detection of five circulating antigens in patients with head and neck squamous cell carcinoma.

Five tumor markers (CEA, Ferritin, CA-50, TPA and SCC) were assayed in 54 patients with ear, nose and throat (ENT) cancers in early and advanced stages. The specificity of these markers always exceeded 95%. Their sensitivity ranged from 13 to 43%, and reached 72% as a combination of all five markers. No distinction was found between early and advanced stage of illness. These markers seem to have no distinct function in ENT oncological diagnosis and follow-up because objective data is easily available even in early tumors.

Aged↗
PubMedDate not supplied

[Prognostic value of tumor markers in the follow up of malignant neoplasms of the head and neck].

A group of 54 patients with previously untreated ENT malignancies were studied and findings regarding five markers generally associated with cancers (CEA, SCC, TPA, CA 50 and ferritin) are presented. The specificity of these markers always proved to be greater than 95% while their sensitivity ranged from 13% to 43%, reaching 72% as a combination of all five markers. The results obtained during follow-up on 21 randomized patients was not satisfactory due to poor sensitivity. In the opinion of the authors, the five markers assayed appear to have no distinct function in monitoring ENT cancers. The sole exception to this is SCC which presents a moderate correlation (60%) with tumor growth.

Aged↗